Integre Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Integre Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-18,411	Closed	-$582K	–	161
2015 Q4	$582K	Sell	18,411 -5,847	-24%	-$207K	0.14%	110
2015 Q3	$835K	Buy	24,258 +262	+1%	+$7.92K	0.2%	85
2015 Q2	$755K	Sell	23,996 -274	-1%	-$8.07K	0.16%	101
2015 Q1	$712K	Buy	24,270 +1,502	+7%	+$35.2K	0.14%	106
2014 Q4	$422K	Buy	22,768 +1	+0%	+$17	0.09%	133
2014 Q3	$399K	Buy	+22,767	New	+$425K	0.08%	138

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Integre Asset Management's MRTX Position: Q1 2016 in Review

Integre Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2016, closing a stake of 18,411 shares — an estimated $582K sold.

Integre Asset Management first reported a position in MRTX in Q3 2014 and held it in 6 quarters. The position peaked at $835K in Q3 2015. 68 funds tracked by Wall St. Rank hold MRTX as of Q1 2016.

Integre Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
Integre Asset Management sold 18,411 Mirati Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $582K.
Integre Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2014 and held it in 6 quarters.
Integre Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $835K in Q3 2015.
68 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Integre Asset Management's 13F filing for Q1 2016, filed 16 May 2016.